What are the mechanisms of resistance to Vorasidenib?

Voxirinib is an oral small molecule inhibitor targeting isocitrate dehydrogenase 1 and 2 (IDH1/2) mutations. It is mainly used to treat tumors such as low-grade gliomas carrying IDH mutations. Although vorsidenib shows good efficacy in early treatment, some patients may develop drug resistance as the treatment time prolongs. The drug resistance mechanism is complex and involves multiple levels.

IDHDynamic changes in mutations are one of the important factors in vorsidenib resistance. In some patients, tumor cells may acquire new mutations that change the conformation of the IDH enzyme, thereby reducing the ability of voroxiranib to bind to its target. Such acquired mutations may occur at new positions in IDH1 or IDH2, resulting in a decrease in the drug's inhibitory effect on the target and allowing tumor cells to regain their growth advantage.

Activation of compensatory metabolic pathways may also lead to vorsidenib resistance. Vorsidenib inhibits the activity of IDH mutant enzyme and reduces the level of 2-hydroxyglutarate (2-HG), thereby affecting cell epigenetic regulation and differentiation status. However, tumor cells may activate other metabolic pathways, such as enhancing fatty acid oxidation, glutamine metabolism, etc., to bypass the metabolic blockade caused by IDH inhibition, thereby continuing to maintain proliferation and survival.

Tumor cell heterogeneity and clonal evolution also contribute to the development of drug resistance. During treatment, some tumor clones that are sensitive to vorsidenib are eliminated, but some preexisting resistant clones may gradually expand and become dominant clones after treatment. This clonal selection pressure allows tumors to progress despite treatment and manifest as radiographic deterioration or recurrence.

In summary, the mechanisms of voroxiranib resistance include IDH mutation site changes, alternative activation of metabolic pathways, and clonal evolution. Future treatment strategies may require the combination of other targeted drugs, immunotherapy, or the use of biomarkers for real-time monitoring to delay the occurrence of drug resistance and improve treatment efficacy.

Reference materials:https://www.drugs.com/donanemab.html